| 7.6 0.57 (8.11%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.76 | 1-year : | 10.82 |
| Resists | First : | 8.36 | Second : | 9.26 |
| Pivot price | 7.51  |
|||
| Supports | First : | 6.9 | Second : | 5.74 |
| MAs | MA(5) : | 7.2 |
MA(20) : | 7.73 |
| MA(100) : | 7.41 |
MA(250) : | 6.96 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 12.5 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 9.34 | Low : | 5.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MASS ] has closed below upper band by 45.2%. Bollinger Bands are 5.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.25 - 7.3 | 7.3 - 7.34 |
| Low: | 6.79 - 6.83 | 6.83 - 6.88 |
| Close: | 6.94 - 7.02 | 7.02 - 7.11 |
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Wed, 29 Jul 2026
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - Benzinga
Wed, 29 Jul 2026
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference - Business Wire
Wed, 29 Jul 2026
Roth/MKM initiates 908 Devices stock with buy rating, $11 target - Investing.com
Tue, 28 Jul 2026
908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026 - BioSpace
Tue, 28 Jul 2026
Press Release: 908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026 - Moomoo
Tue, 28 Jul 2026
MASS|908 Devices Inc.|Price:7.125|Chg%:-0.015 - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 41 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 82.8 (%) |
| Shares Short | 3,230 (K) |
| Shares Short P.Month | 3,210 (K) |
| EPS | -0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.58 |
| Profit Margin | -62.5 % |
| Operating Margin | -48.6 % |
| Return on Assets (ttm) | -7.6 % |
| Return on Equity (ttm) | -24.2 % |
| Qtrly Rev. Growth | 13.6 % |
| Gross Profit (p.s.) | 0.73 |
| Sales Per Share | 1.4 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | 14 (M) |
| PE Ratio | -7.84 |
| PEG Ratio | 0 |
| Price to Book value | 2.11 |
| Price to Sales | 5.39 |
| Price to Cash Flow | -41.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|